Cellectisの価格/簿価
Cellectisの価格/簿価は何ですか。
Cellectisの価格/簿価は0.53です。
価格/簿価の定義は何ですか。
株価純資産倍率は、会社の株価と1株当たりの簿価との比率を表します。
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
NASDAQのセクタHealth Careにおける価格/簿価の企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似の価格/簿価
- Barclays Plcの価格/簿価は0.53です。
- Wealthy Wayの価格/簿価は0.53です。
- Vodatel Networksの価格/簿価は0.53です。
- Shiva Global Agro Industriesの価格/簿価は0.53です。
- Dishman Carbogen Amcisの価格/簿価は0.53です。
- CLPS Incの価格/簿価は0.53です。
- Cellectisの価格/簿価は0.53です。
- Ramco Industriesの価格/簿価は0.53です。
- Guerbet SAの価格/簿価は0.53です。
- Kingworld Medicinesの価格/簿価は0.53です。
- Serinus plcの価格/簿価は0.53です。
- MI Homesの価格/簿価は0.53です。
- Global Ship Lease Incの価格/簿価は0.53です。